Skip to main content

Model Predicts Need for Bone Marrow Sampling in Monoclonal Gammopathy of Undetermined Significance

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, April 1, 2024 -- A recently developed multivariable model can accurately predict smoldering multiple myeloma (SMM) or worse in persons with presumed monoclonal gammopathy of undetermined significance (MGUS), according to a study published online April 2 in the Annals of Internal Medicine.

Elias Eythorsson, M.D., Ph.D., from the University of Iceland in Reykjavik, and colleagues developed a multivariable prediction model that predicts the probability that a person with presumed MGUS has 10 percent or greater bone marrow plasma cells (SMM or worse by bone marrow criteria) to inform the decision to obtain a bone marrow sample. In addition, performance of the prediction model was compared to performance of the Mayo Clinic risk stratification model. The study included 1,043 adults with immunoglobulin G (IgG), IgA, light-chain, and biclonal MGUS and an interpretable bone marrow sample.

The researchers found that the C-statistic was 0.85 for SMM or worse, and calibration was excellent. Sensitivity and specificity were 86 and 67 percent, respectively, at a threshold of 10 percent predicted risk for SMM or worse; positive and negative predictive values were 32 and 96 percent, respectively. Across a range of plausible low-risk thresholds, the net benefit for the decision to refer for sampling was 0.13 to 0.30 higher compared with the Mayo Clinic model.

"Persons with predicted risks below the relevant low-risk threshold could safely defer bone marrow sampling and be managed by primary care physicians as presumed MGUS," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States

THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...

Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening

WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...

American College of Surgeons, Oct. 19-22

The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.